Juan Manuel P.
- Country
- Spain
- Department
- Gastroenterology and Hepatology
Research Overview
- Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Efimosfermin Alfa Safety and Tolerability in Adults with F2‑F3 Metabolic Dysfunction‑Associated Steatohepatitis
- Evaluation of BI 685509 on Portal Hypertension in Patients with Decompensated Cirrhosis Post-First Decompensation Event
- Efficacy and Safety of NNC0194-0499 and Semaglutide in Non-Alcoholic Steatohepatitis with Fibrosis Stages F2-F4: A Dose-Ranging, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 130 of 229 partner sites.
Specializations
Liver Disease Expertise
The investigator specializes in treating non-alcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH), with particular focus on various stages of liver fibrosis and cirrhosis.
- Pre-cirrhotic liver conditions
- Compensated cirrhosis management
- Portal hypertension treatment
Advanced experience in evaluating liver histology and monitoring disease progression through specialized imaging techniques.
Metabolic Health
Focuses on the intersection of metabolic disorders and liver disease, including research into conditions associated with obesity and related metabolic complications.
- Liver fat reduction strategies
- Weight management protocols
- Metabolic dysfunction treatment
Expertise in treating patients with complex metabolic conditions affecting liver health.
Therapeutic Innovation
Investigates novel therapeutic approaches for liver diseases, including combination therapy strategies and innovative treatment modalities for fibrosis regression.
- Advanced therapeutic agents
- Liver disease progression markers
- Clinical outcomes assessment
Evaluates emerging treatments for liver diseases with focus on long-term patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.